SCHEMBL8770154

SCHEMBL8770154

O=C(Nc1ccc(C(=O)c2ccc(NC(=O)c3ccc(-n4cccn4)cc3)cc2)cc1)c1ccc(-n2cccn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.55
KMT2A Q03164 6/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 1/20 0.55
ALDH1A1 P00352 4/20 0.55
RXFP1 Q9HBX9 3/20 0.55
KDM4E B2RXH2 1/20 0.55
TP53 P04637 1/20 0.52
FFAR1 O14842 1/20 0.51
MAPT P10636 4/20 0.50
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
MDM2 Q00987 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PKM P14618 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.48
SIRT1 Q96EB6 1/20 0.48
SIRT3 Q9NTG7 1/20 0.48
TBK1 Q9UHD2 1/20 0.48
F10 P00742 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769758 0.91 ALDH1A1 (0.55) MEN1KMT2ARAB9AALDH1A1RXFP1
SCHEMBL3377974 0.90 RAB9A (0.55) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL4253031 0.90 RAB9A (0.62) MEN1KMT2ARAB9AALDH1A1RXFP1
SCHEMBL13701946 0.89 GAA (0.63) MEN1KMT2AALDH1A1RXFP1KDM4E
SCHEMBL3871686 0.87 GCGR (0.59) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL17303476 0.86 NOTUM (0.58) KMT2AALDH1A1RXFP1KDM4ETP53
N-Phenylbenzamide SCHEMBL27770845 0.84 HTT (0.55) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL21254779 0.83 ALDH1A1 (0.48) MEN1KMT2ARAB9AALDH1A1RXFP1
SCHEMBL2401139 0.82 NOTUM (0.53) MEN1KMT2ARAB9ANPC1ALDH1A1
SCHEMBL13701850 0.80 RAB9A (0.54) MEN1KMT2ARAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL MEN1 1370/4885KMT2A 2225/4885RAB9A 4230/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MEN1 1395/4885KMT2A 806/4885RAB9A 3140/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF MEN1 1395/4885KMT2A 806/4885RAB9A 3140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.